Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628 - Wikidata - awgldk - TriplyDB

Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628

Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628

http://www.wikidata.org/entity/Q33430717

about

Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc Alpha-fetoprotein elevation in NUT midline carcinoma: a case report A Pipeline for Drug Target Identification and Validation Replication Study: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents Targeting BET bromodomain proteins in solid tumors The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma BET inhibitors: a novel epigenetic approach.Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.Fusion proteins in head and neck neoplasms: Clinical implications, genetics, and future directions for targeting.The impact of immunohistochemistry on the classification of lung tumors.Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck.Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature.NUT midline carcinoma of the larynx: an international series and review of the literature.BET Bromodomain Proteins as Cancer Therapeutic Targets.Transcriptional Addiction in Cancer.Targeting Cancer Cells with BET Bromodomain Inhibitors.Striatal H3K27 Acetylation Linked to Glutamatergic Gene Dysregulation in Human Heroin Abusers Holds Promise as Therapeutic Target.A Phase Separation Model for Transcriptional Control.New tumor entities in the 4th edition of the World Health Organization classification of head and neck tumors: Nasal cavity, paranasal sinuses and skull base.NUT carcinoma in children and adults: A multicenter retrospective study.Cytopathologic features of NUT midline carcinoma: A series of 26 specimens from 13 patients.Nuclear protein in testis carcinoma of the mediastinum: a case report.Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma.Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer.Classification of pulmonary neuroendocrine tumors: new insights.Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma.Uncovering BRD4 hyperphosphorylation associated with cellular transformation in NUT midline carcinoma.NUT midline carcinoma as a primary lung tumor: a case report.Targeting bromodomain and extraterminal proteins in breast cancer.Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition.The Impact of Histologic Phenotype in the Treatment of Sinonasal Cancer.Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma-an aggressive and fatal disease.Update on Immunohistochemistry for the Diagnosis of Lung Cancer.BRD4 facilitates replication stress-induced DNA damage response.miR-3140 suppresses tumor cell growth by targeting BRD4 via its coding sequence and downregulates the BRD4-NUT fusion oncoprotein.Genetic profiling of poorly differentiated sinonasal tumours.

P2860

Q28559676-80F42EE5-CB1D-4B0E-B7B4-002B03711905 Q33560408-8645F7EC-66CD-4BCC-AB94-0477EC7D34B7 Q33793854-A46A2D3C-7495-42F4-A6C7-ECAAA82FCC10 Q33842529-31820C0E-200B-4977-886E-159DEC6C21B3 Q37330876-B84A9028-C96C-4B1F-A793-B0F5CF1726F5 Q37619860-3F8CF41C-8073-422F-A120-A76E3CD57429 Q37702577-BB478E37-A854-4520-A08B-DF21D70B8474 Q37733990-D8C5AED7-7038-4CCF-88DD-6D79C995194F Q37735592-9D0AD8E4-9223-49DD-A9E7-8F8E427B73AD Q38609772-A2D60989-B62C-44A2-A3D2-512B985211C0 Q38707684-297DF105-6DCB-47B2-B6A4-7A793FB24C4A Q38710711-1C21CAE1-BF35-4FE3-8C3B-82419B01FF6F Q38820509-391378D2-FF1A-4775-A4ED-CF34B50EBC99 Q38822314-4544CB0F-81EA-4730-8EF6-8A46A11DB279 Q38923801-41BDB38B-E398-40A4-B7F8-1A704CB67233 Q39024306-45C836D1-AF40-4ABB-A590-6AF83EDE3A57 Q39031667-C76999AA-3810-4165-B8A5-38B0758F3578 Q39071349-C63E8533-35F4-4967-A99D-65834E02676A Q39130428-3969DD82-0E90-4403-881B-D9B23350347E Q39141456-A7942673-8846-42A2-90F9-7FDE83D29FBC Q39173763-AA0504C6-3014-474D-B992-A74509B9450F Q39199057-62DA8A0A-E51F-4A98-B660-BB3B3BB9B145 Q39263682-3704F9EF-7204-45C0-8B4B-FE77B5FB3562 Q39393379-506F0E3A-74D8-4CEF-8086-F4A6178EAE57 Q40657896-CF919663-3995-49C9-B42A-E67AE6790379 Q41899931-8FAECEE5-0C7F-46C0-ABD5-C9ED433A83BB Q42367759-963189D4-7E24-4290-99B6-83A4399E4102 Q42775768-214C408D-003F-4138-A602-9BB422B6E3DE Q45140096-23B2ADE7-D3A6-4E9E-A343-D23AD476AC75 Q45141257-EE57EBB4-6C69-4FC9-9295-FEFFD29A927A Q47119688-13984C3B-630E-4AA1-8A13-1C3EB18F9235 Q47193460-AEDC21A3-0EEA-4314-8906-335796D71E24 Q47385983-107C6FEA-37AB-476B-9E0A-B101C1453DBA Q48023755-452383ED-1A48-427B-BA1C-0DAD9E23B23E Q48035221-B9AD442A-1CE8-4A3C-A621-55E0000830BF Q49166169-94D45582-48D9-4AA0-8D1D-EEEDF6E1C5FD Q51733982-8EFBAD2D-470C-48B2-B5CE-CBDF8C86B556 Q52595313-4C2E0ACA-855B-416B-9B1E-0D6F8176E0D2 Q52655303-D9CB2DFB-357D-4515-802A-3632DC6B2BEF Q52673137-126C731A-745A-48D6-98EC-D93F170F38A3

P2860

Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628

http://www.wikidata.org/entity/Q33430717

description

2016 nî lūn-bûn

@nan

2016 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մարտին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Clinical Response of Carcinoma ...... omain Inhibitor OTX015/MK-8628

@ast

Clinical Response of Carcinoma ...... omain Inhibitor OTX015/MK-8628

@en

type

label

Clinical Response of Carcinoma ...... omain Inhibitor OTX015/MK-8628

@ast

Clinical Response of Carcinoma ...... omain Inhibitor OTX015/MK-8628

@en

prefLabel

Clinical Response of Carcinoma ...... omain Inhibitor OTX015/MK-8628

@ast

Clinical Response of Carcinoma ...... omain Inhibitor OTX015/MK-8628

@en

P1433

Q33430717-978AE45E-EF5B-49A7-B331-206F2ECF07BA

P1476

Q33430717-6C9C19AC-F6EB-482F-B068-6E4AC725FDBA

P2093

Q33430717-143B5C6F-99B8-4B6A-9B1F-104388126C95

Q33430717-3DE6384B-3352-49AA-88DF-B2BC87B29C81

Q33430717-4E7D8E32-2402-4F10-B670-BB0B08A4B05A

Q33430717-50A84D3D-9496-417E-AE8B-66D48C460B4F

Q33430717-A3C11880-2F63-4860-86AC-50130ECB9559

Q33430717-B54187EF-FB53-4527-9A13-5DFBA3B71988

Q33430717-D90D9399-7F58-4F7A-B22E-A5EA98CE0DAD

P2860

Q33430717-08F1690D-7692-4ACC-A911-BD9C069508D7

Q33430717-19FC5710-2C90-47D7-8583-9B262FAB2684

Q33430717-1A7C83AA-0D3F-4284-A4DB-81A8EBA929DE

Q33430717-1E75CAB0-5AC8-4E7D-A77A-3B884B417821

Q33430717-379C0480-4177-4A05-BFD1-369A21E4D6E4

Q33430717-3A197640-E9AC-4314-88E3-E928EC175235

Q33430717-3D326DC4-55F2-466B-B2B2-15281AD7B5A3

Q33430717-3E448E01-87F6-4FCB-8C6D-95A14E77894F

Q33430717-4BA23E0E-1204-400D-9E1A-BDDEC69E9708

Q33430717-8E1563E3-4C2E-4FA7-BB5E-F8A83A223FD8

P304

Q33430717-61E90217-26F1-4F03-A9F4-F92E1E012301

P31

Q33430717-28F44CF8-1B0B-4275-90A9-65203683A279

P356

Q33430717-0782F8EB-D696-4E15-8C33-1C4479DDB901

P433

Q33430717-1A7F1796-CB46-4337-B5CC-BD9FC6E4A44E

P478

Q33430717-AA98EEA5-A492-4D35-B1D6-30F745363213

P50

Q33430717-80A36CAF-F245-49B2-A377-AB802AAD6FC0

Q33430717-871935EC-317F-4C1F-922C-44FCDD40A693

Q33430717-FE69F017-A8A3-4E13-B346-D01FB01BF4AD

P577

Q33430717-322FDF93-EF59-4C10-B0CE-3EB0FF1EE952

P698

Q33430717-BED070A5-E954-45BF-8AF8-4FD68146C44B

P932

Q33430717-4C98E4D8-606F-42EB-84D0-C52B2F133E8C

P356

2159-8290.CD-15-1335

P1433

Cancer Discovery

P1476

Clinical Response of Carcinoma ...... omain Inhibitor OTX015/MK-8628

@en

P2093

Anastasios Stathis

http://www.w3.org/2001/XMLSchema#string

Carlos Gomez-Roca

http://www.w3.org/2001/XMLSchema#string

Christopher A French

http://www.w3.org/2001/XMLSchema#string

Giuseppe Pelosi

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Delord

http://www.w3.org/2001/XMLSchema#string

Mohamed Bekradda

http://www.w3.org/2001/XMLSchema#string

Thibault de La Motte Rouge

http://www.w3.org/2001/XMLSchema#string

P2860

Selective inhibition of BET bromodomains

BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma

Comprehensive genomic characterization of head and neck squamous cell carcinomas

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

Selective inhibition of tumor oncogenes by disruption of super-enhancers

Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.

Clinicopathologic features and long-term outcomes of NUT midline carcinoma.

Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody.

High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing

NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism.

P304

492-500

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-15-1335

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Filippo de Braud

Emmanuelle Uro-Coste

P577

2016-03-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26976114

http://www.w3.org/2001/XMLSchema#string

P932

4854801

http://www.w3.org/2001/XMLSchema#string